



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BI605906

Cat. No.:	HY-13019
CAS No.:	960293-88-3
Molecular Formula:	C ₁₇ H ₂₂ F ₂ N ₄ O ₃ S ₂
Molecular Weight:	432.51
Target:	IKK
Pathway:	NF-κB
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (115.60 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	2.3121 mL	11.5604 mL	23.1209 mL
		5 mM	0.4624 mL	2.3121 mL	4.6242 mL
		10 mM	0.2312 mL	1.1560 mL	2.3121 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (2.89 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.25 mg/mL (2.89 mM); Suspended solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	BI605906 is a novel IKKβ inhibitor with an IC ₅₀ value of 380 nM when assayed at 0.1 mM ATP.
IC ₅₀ & Target	IKKβ 380 nM (IC ₅₀ , at 0.1 mM ATP)
In Vitro	BI605906 is an inhibitor of IKKβ with improved selectivity. BI605906 inhibits IKKβ in vitro with an IC ₅₀ value of 380 nM when assayed at 0.1 mM ATP. The only other protein kinase that is inhibited of over 100 tested, which include IKKα, IKKε and TBK1, is the insulin-like growth factor 1 (IGF1) receptor (IC ₅₀ =7.6 μM). BI605906 partially inhibits the IL-1-stimulated activation of IKKε/TBK1 ^[1] . In primary mouse hepatocytes, Metformin treatment for 3 hours suppresses TNFα-induced degradation of the NF-κB negative regulator IκB, while modulating AMPK and MTOR signaling in a dose-dependent manner. The magnitude of

the effect on I κ B is comparable with BI605906. Unlike Metformin, BI605906 (10 μ M) does not suppress signaling downstream of mTOR nor does it activate AMPK. TNF- α -dependent expression of CINC-1/CXCL1, CXCL2, IL-1 β , and IL-6 is strongly inhibited by both Metformin and BI605906 (10 μ M)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Primary hepatocytes are incubated in serum-free medium overnight and then stimulated for 3 h with or without 2 mM Metformin and TNF- α . In addition, cells are incubated with/without 10 μ M BI605906 or 100 nM Rapamycin, before lysis and immunoblotting^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Cell. 2017 Jun 1;66(5):698-710.e5.
- Proc Natl Acad Sci U S A. 2023 Dec 12;120(50):e2313148120.
- J Biol Chem. 2020 Oct 16;295(42):14325-14342.
- Sci Rep. 2019 Jan 17;9(1):193.
- Cytokine. 2023 Jul 20;169:156302.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Clark K, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104.

[2]. Cameron AR, et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016 Aug 19;119(5):652-65.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA